GHK-Cu: Identity, Topical and Injectable Claims and Evidence
GHK-Cu is a copper-binding tripeptide used in skincare. This page separates its identity, cosmetic and injectable claims, human trials, safety and regulatory status.
Content last updated . This page has not been medically reviewed.
Overview and classification
GHK-Cu is the copper(II) complex of GHK, a three-amino-acid peptide (glycyl-L-histidyl-L-lysine). It is best known as a cosmetic ingredient, and it is also promoted online as an injectable "research" peptide. Those are two different claims with different evidence and different rules. This is the canonical GHK-Cu page; for the wider ingredient family see Signal Peptides, Carrier Peptides and Copper Peptides and Skin and Cosmetic Peptides. Evidence labels used: preclinical (cells/animals only), promising but limited, mixed, insufficient evidence, and marketing claim.Exact identity: GHK, GHK-Cu and relatives
A 2026 evidence-mapping review stresses that the literature often treats GHK-Cu as one active ingredient even though coordination state, stability and release depend on the formulation. It separates apo-GHK (no copper), canonical GHK-Cu, GHK-derived copper peptides and other copper-peptide systems. [1] A topical review adds that GHK-Cu (the metal complex) and palmitoyl-GHK (a fatty-acid-modified version) are different ingredients. [2] A cosmetic label saying "copper tripeptide" or "GHK" does not by itself tell you which form or how much copper is present.What research shows
Cell and animal studies. Preclinical data consistently support effects on matrix remodeling, epithelial repair, inflammation and redox control, and blood-vessel growth. [1] Label: preclinical (cells/animals only). These tissue changes are not evidence of human skin or injury recovery.Topical use in people.
| Study | Design | Result |
|---|---|---|
| Miller 2006, after CO2 laser resurfacing | 13 patients, randomized, with vs without GHK-Cu skin care, blinded evaluation | No significant difference in redness or in wrinkles or skin quality on objective assessment; patient-reported skin quality was higher with GHK-Cu (P = .04). [3] |
| 2026 split-face eyebrow study (as summarized by a review) | 18 participants | Reported positive cosmetic hair outcomes, but GHK-Cu form and local exposure were not defined. [1] |
| Phase 2 wound-healing trial NCT07437586 | Registered, recruiting, estimated 60 healthy adults, vehicle-controlled gel on standardized small wounds, sponsored by a company | No results; a registration is not evidence of benefit. [4][1] |
A 2025 review concluded there is a surprising absence of clinical studies of GHK-Cu and palmitoyl-GHK for wrinkles, even though cell studies are encouraging. [2] The 2026 mapping review concluded clinical evidence is sparse and that GHK-Cu should be regarded as promising but unproven rather than a validated regenerative drug. [1] Label: mixed to insufficient evidence for visible skin benefits; promising but limited at best.
Skin penetration. Whether GHK-Cu reaches its intended site in skin is a recurring problem; it is water-loving and unstable in formulations. [2] See Peptides in Topical Formulations.
Injectable use. I searched PubMed and ClinicalTrials.gov for human injectable GHK-Cu trials and found none with results. Proper evidence not found. Injectable claims for healing, hair or "anti-aging" are marketing claims in this library.
Special groups
People who are pregnant, breastfeeding or have copper-handling or skin conditions have no safety data in the sources read. Ask a clinician or dermatologist.Quality and labeling
Total peptide content, copper occupancy and release often are not reported, so two products with the same name can differ. [1]Related guides
Cosmetic Peptide Outcomes compares ingredients; How to Evaluate Peptide Claims helps with marketing.Frequently asked questions
Is GHK-Cu the same as GHK?
No. GHK is the three-amino-acid peptide; GHK-Cu is its copper complex, and other derivatives exist. [1]
Does GHK-Cu reduce wrinkles?
Evidence is thin. A reviewed human trial found no objective improvement, and a 2025 review found few clinical studies. [3][2]
Is injectable GHK-Cu approved?
I found no approval. The FDA lists it as a nominated bulk substance that was withdrawn from category 2, with safety caveats. [5]
Does it grow hair?
Proper evidence not found beyond a small 2026 split-face study with undefined product form. [1]
Are there ongoing trials?
Yes, a Phase 2 topical wound trial is recruiting and has no results. [4]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Regulatory status (read 2026-10-22)
| Jurisdiction | Product and use | What the official source says |
|---|---|---|
| United States (FDA) | Bulk GHK-Cu for injectable compounding | Listed on the FDA page of substances "nominated but withdrawn" from category 2, with the note that injectable GHK-Cu may pose immune risk from aggregation and impurities and that human safety data are limited. The page was current as of 22 April 2026. [5] |
| Other countries | Any use | Not verified. |
| Cosmetics | Topical products | Not verified from a regulator or the ingredient safety panel this session. |
A nominated-but-withdrawn listing is not an approval. Compounding is not approval either. This is not legal advice, and laws change.
Safety
References
- Mateescu DM et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo. Pharmaceutics 2026. PubMed 42797253. Read 2026-10-22.
- Mortazavi SM et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. Bioimpacts 2025. PubMed 39963574. Read 2026-10-22.
- Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006. PubMed 16847171. Read 2026-10-22.
- ClinicalTrials.gov. NCT07437586, Topical GHK-Cu Gel for Acute Skin Wound Healing (Phase 2, recruiting). NCT07437586, Topical GHK-Cu Gel for Acute Skin Wound Healing (Phase 2, recruiting). Read 2026-10-22.
- U.S. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). FDA. Read 2026-10-22.